Neuromodulatory actions of endocannabinoids in pain and sedation

Advances in Experimental Medicine and Biology

Volumn 523, Issue , 2003, Pages 215-225

  De Petrocellis, Luciano ^a   Bisogno, Tiziana ^a   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ANANDAMIDE; CALCIUM CHANNEL T TYPE; CALCIUM ION; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DRONABINOL; DYNORPHIN A; ENDOCANNABINOID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; NORADRENALIN; PALMIDROL; PHOSPHOLIPASE C; POTASSIUM CHANNEL; RIMONABANT; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ANTINOCICEPTION; BASAL GANGLION; CONFERENCE PAPER; HIPPOCAMPUS; HUMAN; NEUROMODULATION; NOCICEPTION; NONHUMAN; OLFACTORY BULB; PHOSPHOLIPID METABOLISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR DENSITY; SEDATION; SYNAPTIC INHIBITION; THALAMUS; TISSUE DISTRIBUTION; ANIMAL; CONSCIOUS SEDATION; DRUG EFFECT; METABOLISM; NERVOUS SYSTEM; PAIN; REVIEW;

ANIMALS; CANNABINOIDS; CONSCIOUS SEDATION; HUMANS; NERVOUS SYSTEM; PAIN;

EID: 2342468749     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9192-8_19     Document Type: Conference Paper

References (94)

1. V. Di Marzo, 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochem-istry and possble physiopathological relevance, Biochim. Biophys. Acta 1392:153 (1998).
2. W. A. Devane, L. Hanus, A. Breuer, R. G. Pertwee, L. A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger, and R. Mechoulam, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science 258:1946 (1992).
3. L. Hanus, A. Gopher, S. Almog, and R. Mechoulam, Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor, J. Med. Chem. 36:3032 (1993).
4. R. Mechoulam, S. Ben-Shabat, L. Hanus, M. Ligumsky, N. E. Kaminski, A. R. Schatz, A. Gopher, S. Almog, B. R. Martin, D. R. Compton, R. G. Pertwee, G. Griffin, M. Bayewitch, J. Barg, and Z. Vogel, Identifation of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors, Biochem. Pharmacol. 50:83 (1995).
5. T. Sugiura, S. Kondo, A. Sukagawa, S. Nakane, A. Shinoda, K. Itoh, A. Yamashita, and K. Waku, 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain, Biochem. Biophys. Commun. 215:89 (1995).
6. L. Hanus, S. Abu-Lafi, E. Fride, A. Breuer, Z. Vogel, D. E. Shalev, I. Kustanovich, R. Mechoulam R., 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A. 98:3662 (2001).
7. D. M. Lambert, and V. Di Marzo, The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr. Med. Chem.; 6:7571999.
8. V. Di Marzo, Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 65:645 (1999).
9. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J. C. Schwartz, and D. Piomelli D., Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686 (1994).
10. G. Petersen, and H. S. Hansen, N-acylphosphatidylethanolamine-hydrolysing phospholipase D lacks the ability to transphosphatidylate. FEBS Lett. 455:41 (1999).
11. N. Ueda, Q. Liu, K Yamanaka K., Marked activation of the N-acyl-phosphatidyl-ethanolamine-hydrolyzing phosphodiesterase by divalent cations. Biochim. Biophys. Acta 1532:121 (2001).
12. H. H. Schmid, P. C. Schmid, V. Natarajan, 1996 The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 80:133.
13. V. Di Marzo, L. De Petrocellis, T. Sugiura, and Waku, Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227:281 (1996).
14. N. Stella, P. Schweitzer P.D. Piomelli, A second endogenous cannabinoid that modulates long-term potentiation. Nature 388:773 (1997).
15. T. Bisogno, D. Melck, L. De Petrocellis, and V. Di Marzo, Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin, J. Neurochem. 72:2113 (1999).
16. R. G. Pertwee, Pharmacology of cannabinoid CB1 and CB2 receptors, Pharmacol. Ther. 74:129 (1997).
17. M. Herkenham, A. B. Lynn, M. D. Little, M. R. Johnson, L. S. Melvin, B. R. de Costa, and K. C. Rice, Cannabinoid receptor localization in brain, Proc. Natl. Acad. Sci. U.S.A. 87:1932 (1990).
18. F. Maingret, A. J. Patel, M. Lazdunski, and E. Honore, The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1, EMBO J. 20:47 (2001).
19. J. Chemin, A. Monteil, E. Perez-Reyes, J. Nargeot, and P. Lory P, Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide, EMBO J. 20:7033 (2001).
20. P. M. Zygmunt, J. Petersson, D. A. Andersson, H. Chuang, M. Sorgard, V. Di Marzo, D. Julius, and E. D. Hogestatt, Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide, Nature 400:452 (1999).
21. D. Smart, M. J. Gunthorpe, J. C. Jerman, S. Nasir, J. Gray, A. I. Muir, J. K. Chambers, A. D. Randall, and J. B. Davis, The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1), Br. J. Pharmacol. 129:227 (2000).
22. V. Di Marzo, T. Bisogno, and L. De Petrocellis L., Anandamide: some like it hot, Trends Pharmacol. Sci. 22:346 (2001).
23. V. Di Marzo, L. De Petrocellis, F. Fezza, A. Ligresti, and T. Bisogno, Anandamide Receptors, Prostagl. Leukotr. Essent. Fatty Acids., 66:377-391 (2002).
24. L. De Petrocellis, T. Bisogno, M. Maccarone, J. D. Davis, A. Finazzi-Agrò, and V. Di Marzo, The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism, J. Biol. Chem. 276:12856 (2001).
25. V. Di Marzo, T. Bisogno, T. Sugiura, D. Melck, and L. De Petrocellis, The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide, Biochem. J. 331:15 (1998).
26. C. J. Hillard, and A. Jarrahian, The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes, Chem. Phys. Lipids 108:123 (2000).
27. F. Fezza, T. Bisogno, A. Minassi, G. Appendino, R. Mechoulam, and V. Di Marzo, Inactivation mechanisms and a sensitive method for the quantification of the putative novel endocannabinoid, noladin ether, in rat brain tissue and cells, FEBS Letts., 513:294-298 (2002).
28. C. J. Hillard, W. S. Edgemond, A. Jarrahian, and W. B. Campbell, Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion, J. Neurochem. 69:631 (1997).
29. B. F. Cravatt, D. K. Giang, S. P. Mayfield, D. L. Boger, R. A. Lerner, and N. B. Gilula, Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, Nature 384:83 (1996).
30. N. Ueda, R. A. Puffenbarger, S. Yamamoto, and D. G. Deutsch, The fatty acid amide hydrolase (FAAH), Chem. Phys. Lipids 108:107 (2000).
31. B. F. Cravatt, K. Demarest, M. P. Patricelli, M. H. Bracey, D. K. Giang, R. R. Martin, and A. H. Lichtman, Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase, Proc. Natl. Acad. Sci. U.S.A. 98:9371 (2001).
32. V. Di Marzo, L. De Petrocellis, and T. Bisogno, Emerging Therapeutic Targets from the Endocannabinoid System. 1. Molecular bases of endocannabinoid formation, action and inactivation, and development of selective inhibitors, Emerging Therapeutic Targets 5:241 (2001).
33. A. C. Howlett, and S. Mukhopadhyay, Cellular signal transduction by anandamide and 2-arachidonoylglycerol, Chem. Phys. Lipids 108:53 (2000).
34. V. Di Marzo, D. Melck, T. Bisogno, L. De Petrocellis, Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, Trends Neurosci. 21:521 (1998).
35. E. Schlicker, and M. Kathmann, Modulation of transmitter release via presynaptic cannabinoid receptors; Trends Pharmacol. Sci. 22:565 (2001).
36. C. Levenes, H. Daniel, P. Soubrie, and F. Crepel, Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells, J. Physiol. 510:867 (1998).
37. B. Szabo, I. Wallmichrath, P. Mathonia, and C. Pfreundtner, Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata, Neuroscience 97:89 (2000).
38. V. Morisset, and L. Urban, Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord, J. Neurophysiol. 86:40 (2001).
39. D. Robbe, G. Alonso, F. Duchamp, J. Bockaert, and O. J. Manzoni, Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens, J. Neurosci. 21:109 (2001).
40. C. W. Vaughan, M. Connor, E. E. Bagley, and M. J. Christie, Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro, Mol. Pharmacol. 57:288 (2000).
41. N. Auclair, S. Otani, P. Soubrie, and F. Crepel, Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons, J. Neurophysiol. 83:3287 (2000).
42. L. Ferraro, M. C. Tomasini, G. L. Gessa, B. W. Bebe, S. Tanganelli, and T. Antonelli, The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study, Cereb Cortex; 11:728(2001).
43. N. Hajos, C. Ledent, and T. F. Freund, Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus, Neuroscience 106:1(2001).
44. P. K. Chan, S. C. Chan, and W. H. Yung, Presynaptic inhibition of GABAergic inputs to rat substantia nigra pars reticulata neurones by a cannabinoid agonist, Neuroreport 9:671 (1998).
45. K. Tsou, K. Mackie, M. C. Sanudo-Pena, and J. M. Walker, Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation, Neuroscience 93:969 (1999).
46. I. Katona, B. Sperlagh, Z. Magloczky, E. Santha, A. Kofalvi, S. Czirjak, K. Mackie, E. S. Vizi, and T. F. Freund T. F., GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus, Neuroscience 100:797 (2000).
47. C. W. Vaughan, I. S. McGregor, and M. J. Christie M, Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro, Br. J. Pharmacol. 127:935 (1999).
48. E. A. Jennings, C. W. Vaughan, and M. J. Christie M. J., Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro, J. Physiol. 534:805 (2001).
49. J. Romero, R. de Miguel, J. A. Ramos, and J. J. Fernandez-Ruiz, The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake, Life Sci. 62:351 (1998).
50. Y. P. Maneuf, J. E. Nash, A. R. Crossman, and J. M. Brotchie, Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus, Eur. J. Pharmacol. 308:16 (1996).
51. R. I. Wilson, and R. A. Nicoll, Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses, Nature 410:588 (2001).
52. A. C. Kreitzer, and W. G. Regehr, Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells, Neuron 29:717 (2001).
53. M. A. Diana, C. Levenes, K. Mackie, and A. Marty, Short-Term Retrograde Inhibition of GABAergic Synaptic Currents in Rat Purkinje Cells Is Mediated by Endogenous Cannabinoids, J. Neurosci. 22:200 (2002).
54. T. Maejima, K. Hashimoto, T. Yoshida, A. Aiba, and M. Kano, Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors, Neuron 31:463 (2001).
55. R. I. Wilson, G. Kunos, and R. A. Nicoll, Presynaptic specificity of endocannabinoid signaling in the hippocampus, Neuron 31:453 (2001).
56. N. Varma, G. C. Carlson, C. Ledent, and B. E. Alger, Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus, J. Neurosci. 21:RC188 (2001).
57. A. S. Rice, Cannabinoids and pain, Curr. Opin. Investig. Drugs 2:399 (2001).
58. R. G. Pertwee, Cannabinoid receptors and pain, Prog. Neurobiol. 63:569 (2001).
59. C. Ledent, O. Valverde, G. Cossu, F. Petitet, J. F. Aubert, F. Beslot, G. A. Bohme, A. Imperato, T. Pedrazzini, B. P. Roques, G. Vassart, W. Fratta, and M. Parmentier, Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice, Science 283:401 (1999).
60. A. Zimmer, A. M. Zimmer, A. G. Hohmann, M. Herkenham, and T. I. Bonner, Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice, Proc. Natl. Acad. Sci. U.S.A. 96:5780 (1999).
61. J. M. Walker, S. M. Huang, N. M. Strangman, K. Tsou, and M. C. Sanudo-Pena, Pain modulation by release of the endogenous cannabinoid anandamide, Proc. Natl. Acad. Sci. U.S.A. 96:12198 (1999).
62. I. D. Meng, B. H. Manning, W. J. Martin, and H. L. Fields, An analgesia circuit activated by cannabinoids, Nature 395:381 (1998).
63. J. D. Richardson, L. Aanonsen, and K. M. Hargreaves, Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia, J. Neurosci. 18:451 (1998).
64. J. D. Richardson, S. Kilo,and K. M. Hargreaves, Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors, Pain 75:111 (1998).
65. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli, Control of pain initiation by endogenous cannabinoids, Nature 394:277 (1998).
66. L. Hanus, A. Breuer, S. Tchilibon, S. Shiloah, D. Goldenberg, M. Horowitz, R. G. Pertwee, R. A. Ross, R. Mechoulam, and E. Fride, HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor, Proc. Natl. Acad. Sci. U.S.A. 96:14228 (1999).
67. P. Beaulieu, T. Bisogno, S. Punwar, W. P. Farquhar-Smith, G. Ambrosino, V. Di Marzo, and A. S. Rice, Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat, Eur. J. Pharmacol. 396:85 (2000).
68. W. P. Farquhar-Smith, and A. S. Rice, Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder, Anesthesiology 94:507 (2001).
69. A. Calignano, G. La Rana, and D. Piomelli, Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide, Eur. J. Pharmacol. 419:191 (2001).
70. D. J. Mason, J. Lowe, and S. P. Welch, Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception, Eur. J. Pharmacol. 378:237 (1999).
71. S. P. Welch, and M. Eads, Synergistic interactions of endogenous opioids and cannabinoid systems, Brain Res. 848:183 (1999).
72. S. P. Welch, Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems, Drug Alcohol Depend. 45:39 (1997).
73. V. Di Marzo, C. Breivogel, T. Bisogno, D. Melck, G. Patrick, Q. Tao, A. Szallasi, R. K. Razdan, and B. R. Martin, Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide, Eur. J. Pharmacol. 406:363 (2000).
74. 2 sites of action, Eur. J. Pharmacol., 439:83-92 (2002).
75. M. Tognetto, S. Amadesi, S. Harrison, C. Creminon, M. Trevisani, M. Carreras, M. Matera, P. Geppetti, and A. Bianchi, Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation, J. Neurosci. 21:1104 (2001).
76. S. D. Gauldie, D. S. McQueen, R. Pertwee, and I. P. Chessell, Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints, Br. J. Pharmacol. 132:617 (2001).
77. J. Harris, L. J. Drew, V. Chapman, Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo, Neuroreport 11:2817 (2000).
78. V. Morisset, J. Ahluwalia, I. Nagy, and L. Urban, Possible mechanisms of cannabinoid-induced antinociception in the spinal cord, Eur. J. Pharmacol. 429:93 (2001).
79. J. Ahluwalia, L. Urban, M. Capogna, S. Bevan, and I. Nagy I., Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons, Neuroscience 100, 685 (2000).
80. B. F. Cravatt, O. Prospero-Garcia, G. Siuzdak, N. B. Gilula, S. J. Henriksen, D. L. Boger, R. A. Lerner, Chemical characterization of a family of brain lipids that induce sleep, Science 268:1506 (1995).
81. I. Fedorova, A. Hashimoto, R. A. Fecik, M. P. Hedrick, L. O. Hanus, D. L. Boger, K. C. Rice, and A. S. Basile, Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems, J. Pharmacol. Exp. Ther. 299:332 (2001).
82. D. L. Boger, S. J. Henriksen, and B. F. Cravatt, Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecule., Curr. Pharm. Des. 4:303 (1998).
83. W. B. Mendelson, and A. S. Basile, The hypnotic actions of the fatty acid amide, oleamide, Neuropsychopharmacology 25:S36 (2001).
84. J. F. Cheer, A. K. Cadogan, C. A. Marsden, K. C. Fone, and D. A. Kendall, Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors, Neuropharmacology 38:533 (1999).
85. W. B. Mendelson, and A. S. Basile, The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist, euroreport 10:3237 (1999).
86. R. Mechoulam, E. Fride, L. Hanus, T. Sheskin, T. Bisogno, V. Di Marzo, M. Bayewitch, and Z. Vogel, Anandamide may mediate sleep induction, Nature 389:25 (1997).
87. V. Santucci, J. J. Storme, P. Soubrie, and G. Le Fur, Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis, Life Sci. 58:PL103 (1996).
88. M. Martinez-Vargas, E. Murillo-Rodriguez, R. Gonzalez-Rivera, A. Landa, J. Velazquez-Moctezuma, O. Prospero-Garcia, and L. Navarro, Cannabinoid receptor 1 increases with sleep rebound, Soc. Neurosci. Abstr. 524.22 (2001).
89. E. Murillo-Rodriguez, A. Giuffrida, F. Desarnaud, O. Prospero-Garcia, and D. Piomelli, Diurnal variations of endogenous cannabinoid compounds in csf and brain regions of the rat, Soc. Neurosci. Abstr. 805.2 (2001)
90. G. Lees, M. D. Edwards, A. A. Hassoni, C. R. Ganellin, and D. Galanakis, Modulation of GABA(A) receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA), Br. J. Pharmacol. 124:873 (1998).
91. A. D. Laposky, G. E. Homanics, A. Basile, and W. B. Mendelson, Deletion of the GABA(A) receptor beta 3 subunit eliminates the hypnotic actions of oleamide in mice, Neuroreport 12:4143 (2001).
92. M. D. Aceto, S. M. Scates, R. K. Razdan, B. R. Martin, Anandamide, an endogenous cannabinoid, has a very low physical dependence potential, J. Pharmacol. Exp. Ther. 287:598 (1998).
93. T. W. Klein, B. Lane, C. A. Newton, and H. Friedman, The cannabinoid system and cytokine network, Proc. Soc. Exp. Biol. Med. 225:1 (2000).
94. G. Kunos, Z. Jarai, S. Batkai, S. K. Goparaju, E. J. Ishac, J. Liu, L. Wang, and J. A. Wagner, Endocannabinoids as cardiovascular modulators, Chem. Phys. Lipids 108:159 (2000).